AIM: To investigate the efficacy of intravitreal injection of conbercept on neovascular age-related macular degeneration(ARMD)and its effect on choroidal thickness.

METHODS: A total of 213 patients(345 eyes)with ophthalmologic diseases who were treated in our hospital from March 2014 to December 2017 were randomly divided into control group(n=106, 176 eyes)and observation group(n=107, 169 eyes). The control group was treated with intravitreal injection of triamcinolone acetonide and the observation group was treated with intravitreal injection of conbercept. The efficacy of the two groups and changes in choroidal thickness were compared and analyzed.

RESULTS: There was no significant difference in BCVA and CMT between the two groups before and after injection(P>0.05). However, BCVA and CMT in observation group and control group were significantly better than those before injection(P<0.05), and there was significant difference between before and after injection. There was no significant difference in central retinal thickness and choroid thickness between the two groups at baseline(1, 3, 6mo)(P>0.05). However, the central retinal thickness and choroid thickness at 6mo were significantly lower than those at baseline and 1, 3mo(P<0.05), which were statistically significant. After treatment, the total incidence of complications in the observation group and the control group were 5.7% and 7.7%, respectively, with no significant difference between the two groups(P>0.05).

CONCLUSION: Intravitreal injection of conbercept and triamcinolone acetonide has the same effect, which can not only improve and stabilize the visual acuity of patients, but also reduce the central retinal thickness and choroid thickness effectively. It has obvious curative effect and high safety, and has clinical application value.